title: Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function.
abstract: Impaired cognitive function and enhanced activity of the hypothalamic-pituitary-adrenocortical system are among the cardinal symptoms of major depression in humans that resolve after successful antidepressant treatment. We used a transgenic mouse model expressing antisense RNA complementary to that of glucocorticoid receptor (GR) mRNA to test the hypothesis that reduced GR function can cause these clinical disturbances. The transgenic mice show profound behavioural changes in a number of animal tests that are indicative of cognitive impairment. These mice also have elevated plasma corticotropin concentrations in response to stress. After long-term treatment with moclobemide, a reversible inhibitor of monoamine oxidase type A that acts clinically as an antidepressant, both the behavioural deficits and the hormonal alterations disappeared. These observations suggest that a transgenic mouse with GR dysfunction may be a useful model for investigation of drug effects on the cognitive and neuroendocrine aspects of depression.
authors: Max Planck Institute of Psychiatry, Clinical Institute, Munich, Germany.
authors: A
authors: A
authors: Montkowski
authors: N
authors: N
authors: Barden
authors: C
authors: C
authors: Wotjak
authors: I
authors: I
authors: Stec
authors: J
authors: J
authors: Ganster
authors: M
authors: M
authors: Meaney
authors: M
authors: M
authors: Engelmann
authors: J M
authors: JM
authors: Reul
authors: R
authors: R
authors: Landgraf
authors: F
authors: F
authors: Holsboer
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D001549:Benzamides / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009490:Neurosecretory Systems / Q000187:drug effects / Q000502:physiology; D005082:Physical Exertion / Q000187:drug effects; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000502:physiology*; D012903:Smell / Q000187:drug effects; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D011965:Receptors, Glucocorticoid; D020912:Moclobemide